Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2024-07-18 00:00:00 ET · period of report 2024-07-16 · accession 0001628280-24-032253 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-18 | 2024-07-16 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $1.08 | +525 | 103.4K | +0.5% | +$567 |
| D | 2024-07-18 | 2024-07-16 | MLYS | Rodman David Malcom | Chief Medical Off | S - Sale+OE | $15.00 | -525 | 102.9K | -0.5% | -$7,875 |
| D | 2024-07-18 | 2024-07-16 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -525 | 183.5K | -0.3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-16 | M | A | 525 | $1.08 | 103,398 | D | — | — | |
| 2 | Common | Common Stock | 2024-07-16 | S | D | 525 | $15.00 | 102,873 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| 3 | Derivative | Stock Option | 2024-07-16 | M | D | 525 | $0.00 | 183,483 | D | $1.08 · — to 2032-07-11 | 525 Common Stock | (F3) Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. (F4) The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. |